SI2574341T1 - Učinkovito zdravljenje tumorjev in raka s triciribin fosfatom - Google Patents

Učinkovito zdravljenje tumorjev in raka s triciribin fosfatom

Info

Publication number
SI2574341T1
SI2574341T1 SI200532155T SI200532155T SI2574341T1 SI 2574341 T1 SI2574341 T1 SI 2574341T1 SI 200532155 T SI200532155 T SI 200532155T SI 200532155 T SI200532155 T SI 200532155T SI 2574341 T1 SI2574341 T1 SI 2574341T1
Authority
SI
Slovenia
Prior art keywords
tumors
cancer
effective treatment
triciribine phosphate
triciribine
Prior art date
Application number
SI200532155T
Other languages
English (en)
Inventor
Jin Q. Cheng
Said M. Sebti
Original Assignee
University Of South Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of South Florida filed Critical University Of South Florida
Publication of SI2574341T1 publication Critical patent/SI2574341T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
SI200532155T 2004-03-29 2005-03-29 Učinkovito zdravljenje tumorjev in raka s triciribin fosfatom SI2574341T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55759904P 2004-03-29 2004-03-29
EP12197499.2A EP2574341B1 (en) 2004-03-29 2005-03-29 Effective treatment of tumors and cancer with triciribine phosphate

Publications (1)

Publication Number Publication Date
SI2574341T1 true SI2574341T1 (sl) 2017-08-31

Family

ID=35064290

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200532155T SI2574341T1 (sl) 2004-03-29 2005-03-29 Učinkovito zdravljenje tumorjev in raka s triciribin fosfatom

Country Status (17)

Country Link
US (3) US8435959B2 (sl)
EP (2) EP1737472B1 (sl)
JP (1) JP5647759B2 (sl)
KR (1) KR101173969B1 (sl)
CN (1) CN1984663A (sl)
AU (1) AU2005228410A1 (sl)
CA (1) CA2561513C (sl)
CY (1) CY1119224T1 (sl)
DK (1) DK2574341T3 (sl)
ES (1) ES2629682T3 (sl)
HU (1) HUE032657T2 (sl)
LT (1) LT2574341T (sl)
MX (1) MXPA06011219A (sl)
PL (1) PL2574341T3 (sl)
PT (1) PT2574341T (sl)
SI (1) SI2574341T1 (sl)
WO (1) WO2005094322A2 (sl)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100028339A1 (en) 2004-03-29 2010-02-04 Cheng Jin Q Compositions including triciribine and trastuzumab and methods of use thereof
US20100173864A1 (en) 2004-03-29 2010-07-08 Cheng Jin Q Compositions including triciribine and one or more platinum compounds and methods of use thereof
US20100009928A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and taxanes and methods of use thereof
US20100009929A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof
ES2629682T3 (es) 2004-03-29 2017-08-14 University Of South Florida Tratamiento efectivo de tumores y cáncer con fosfato de triciribina
US20110008327A1 (en) 2004-03-29 2011-01-13 Cheng Jin Q Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof
US20110223154A1 (en) * 2008-05-12 2011-09-15 University Of South Florida Compositions including triciribine and methods of use thereof
US20080063637A1 (en) * 2006-05-19 2008-03-13 The Trustees Of Tufts College Regulation of oncogenesis by Akt-specific isoforms
US8828451B2 (en) 2006-10-04 2014-09-09 University Of South Florida Akt sensitization of cancer cells
EP2182939A2 (en) * 2006-11-06 2010-05-12 Vioquest Pharmaceuticals, Inc. Compositions including triciribine and taxanes and methods of use thereof
WO2008060581A2 (en) * 2006-11-15 2008-05-22 University Of South Florida Compositions including triciribine and trastuzumab and methods of use thereof
TW200831111A (en) * 2006-11-20 2008-08-01 Vioquest Pharmaceuticals Inc Compositions including triciribine and anthracyclin analogs and methods of use thereof
WO2008070100A1 (en) * 2006-12-05 2008-06-12 University Of South Florida Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof
TW200831525A (en) * 2006-12-06 2008-08-01 Vioquest Pharmaceuticals Inc Compositions including triciribine and one or more platinum compounds and methods of use thereof
TW200836749A (en) * 2007-01-09 2008-09-16 Vioquest Pharmaceuticals Inc Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof
US20100093609A1 (en) * 2007-03-29 2010-04-15 John Hilfinger Prodrugs of triciribine and triciribine phosphate
KR101618037B1 (ko) * 2007-07-12 2016-05-04 유니버시티 오브 사우스 플로리다 항종양 활성이 있는 Ａｋｔ/ＰＫＢ 저해제
US8178502B2 (en) 2007-09-07 2012-05-15 University Of South Florida Effective treatment of esophogeal adenocarcinoma using triciribine and related compounds
US10365279B2 (en) 2008-01-25 2019-07-30 Berg Llc Assay system for the assessment of oncogenicity, tumor progression, and treatment efficacy
CA2724246C (en) 2008-05-12 2019-11-26 University Of South Florida Anticancer combination therapy including triciribine
US8501734B2 (en) * 2008-05-26 2013-08-06 Oncotyrol-Center For Personalized Cancer Medicine Gmbh (Ltd.) Medical intervention in haematological cancers
EP2304439A4 (en) 2008-05-29 2012-07-04 Nuclea Biotechnologies Llc ANTI-phospho-AKT ANTIBODY
SG194045A1 (en) 2011-04-01 2013-11-29 Genentech Inc Combinations of akt inhibitor compounds and abiraterone, and methods of use
HUE051096T2 (hu) * 2012-04-26 2021-03-01 Massachusetts Gen Hospital Ágensek és módszerek a sebészeti keratózis kezelésére és megelõzésére
US10508309B2 (en) 2013-05-17 2019-12-17 The General Hospital Corporation Methods for detecting and treating variants of seborrheic keratoses
CN106562986A (zh) * 2015-10-13 2017-04-19 合肥中科普瑞昇生物医药科技有限公司 曲西立滨和/或其代谢产物治疗携带flt3突变型基因的急性白血病的用途
WO2021097401A1 (en) * 2019-11-14 2021-05-20 H. Lee Moffitt Cancer Center And Research Institute, Inc. Combination therapy with protein kinase b activation inhibitor to treat cancer
CN113025651B (zh) * 2021-03-31 2023-03-24 重庆医科大学 靶向HBV核心启动子的药物筛选细胞模型、Triciribine及结构类似物新应用

Family Cites Families (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4018653A (en) 1971-10-29 1977-04-19 U.S. Packaging Corporation Instrument for the detection of Neisseria gonorrhoeae without culture
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4123524A (en) * 1977-06-08 1978-10-31 The United States Of America As Represented By The Department Of Health, Education And Welfare Synthesis of 6-amino-4-methyl-8-(β-D-ribofuranosyl)pyrrolo[4,3,2-de]pyrimido[4,5-C]pyridazine-5'-phosphate as a novel compound and its utility against L-1210 mouse leukemia
DE2820893C2 (de) 1978-05-12 1986-02-20 A. Nattermann & Cie GmbH, 5000 Köln Strukturanaloga von natürlichen Phospholipiden und Verfahren zur Herstellung dieser Verbindungen
DE3164332D1 (en) 1980-10-21 1984-07-26 Boehringer Mannheim Gmbh Phospholipids that contain sulphur, process for their preparation and medicines containing these compounds
US4493832A (en) 1981-07-03 1985-01-15 Fujisawa Pharmaceutical Co., Ltd. Certain glycerol-phosphoryl choline derivatives, compositions containing same and method of using same
EP0077529B1 (de) 1981-10-16 1985-07-17 Sanol Schwarz GmbH Arzneimittelformulierung
US4562179A (en) 1982-04-19 1985-12-31 Fujisawa Pharmaceutical Co., Ltd. Phospholipid derivatives, and pharmaceutical composition of the same
US4424279A (en) 1982-08-12 1984-01-03 Quidel Rapid plunger immunoassay method and apparatus
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
DE3323871A1 (de) 1983-07-02 1985-01-03 A. Nattermann & Cie GmbH, 5000 Köln Neue 1-o-alkyl-3-amino-propan-1,2-diol-2-o-phospholipide, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US5223263A (en) 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
US6448392B1 (en) 1985-03-06 2002-09-10 Chimerix, Inc. Lipid derivatives of antiviral nucleosides: liposomal incorporation and method of use
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5019368A (en) 1989-02-23 1991-05-28 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
DE3872635T2 (de) * 1987-04-09 1992-12-17 Fisons Plc Pentamidin enthaltende pharmazeutische zusammensetzungen.
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
WO1989002733A1 (en) 1987-09-22 1989-04-06 The Regents Of The University Of California Liposomal nucleoside analogues for treating aids
WO1990011079A1 (en) 1989-03-29 1990-10-04 Alcon Laboratories, Inc. Use of monoacyl phosphoglycerides to enhance the corneal penetration of ophthalmic drugs
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US5817638A (en) 1988-07-07 1998-10-06 Nexstar Pharmaceuticals, Inc. Antiviral liponucleosides: treatment of hepatitis B
US6252060B1 (en) 1988-07-07 2001-06-26 Nexstar Pharmaceuticals, Inc. Antiviral liponucleosides: treatment of hepatitis B
US5135736A (en) 1988-08-15 1992-08-04 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
CA2001401A1 (en) 1988-10-25 1990-04-25 Claude Piantadosi Quaternary amine containing ether or ester lipid derivatives and therapeutic compositions
US5759837A (en) * 1989-01-17 1998-06-02 John Hopkins University Chemotherapy for cancer by inhibiting the fatty acid biosynthetic pathway
US5411947A (en) 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US5194654A (en) 1989-11-22 1993-03-16 Vical, Inc. Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
US5463092A (en) 1989-11-22 1995-10-31 Vestar, Inc. Lipid derivatives of phosphonacids for liposomal incorporation and method of use
GR1000688B (el) 1989-12-22 1992-10-08 Sod Conseils Rech Applic Μεθοδος παρασκευης παραγωγων γλυκερινης.
AU7872491A (en) 1990-05-07 1991-11-27 Vical, Inc. Lipid prodrugs of salicylate and nonsteroidal anti-inflammatory drugs
CA2083961A1 (en) 1990-05-29 1991-11-30 Henk Van Den Bosch Synthesis of glycerol di- and triphosphate derivatives
EP0531452A4 (en) 1990-05-29 1993-06-09 Vical, Inc. Synthesis of glycerol di- and triphosphate derivatives
DK0533833T3 (da) 1990-06-13 1996-04-22 Arnold Glazier Phosphorprolægemidler
US5177064A (en) 1990-07-13 1993-01-05 University Of Florida Targeted drug delivery via phosphonate derivatives
US5256641A (en) 1990-11-01 1993-10-26 State Of Oregon Covalent polar lipid-peptide conjugates for immunological targeting
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5149794A (en) 1990-11-01 1992-09-22 State Of Oregon Covalent lipid-drug conjugates for drug targeting
US5543389A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization Covalent polar lipid-peptide conjugates for use in salves
US5798339A (en) * 1990-12-17 1998-08-25 University Of Manitoba Treatment method for cancer
JPH06510020A (ja) 1991-03-29 1994-11-10 ユニバーシティ・オブ・フロリダ 混成リン酸エステル誘導体を経た標的への薬剤供給
JPH07500573A (ja) 1991-07-12 1995-01-19 ネクススター・ファーマシューティカルズ・インコーポレイテッド 抗ウィルス性リポヌクレオシド：ｂ型肝炎の治療
US5554728A (en) 1991-07-23 1996-09-10 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
AU662367B2 (en) 1991-10-28 1995-08-31 Mona Industries, Inc. Phospholipid antimicrobial compositions
US5541287A (en) 1992-06-09 1996-07-30 Neorx Corporation Pretargeting methods and compounds
US5976535A (en) 1992-06-09 1999-11-02 Neorx Corporation Pretargeting protocols for the enhanced localization of cytotoxins to target sites and cytotoxic combinations useful therefore
US5512671A (en) 1993-02-16 1996-04-30 Wake Forest University Ether lipid-nucleoside covalent conjugates
FR2703353B1 (fr) * 1993-03-29 1995-05-05 Rhone Poulenc Rorer Sa Procédé de préparation de dérivés de la beta-phénylisosérine.
WO1994026273A1 (en) 1993-05-12 1994-11-24 Hostetler Karl Y Acyclovir derivatives for topical use
EP0702556B1 (en) 1993-06-10 2002-10-23 Wake Forest University (phospho)lipids for combatting hepatitis b virus infection
WO1996006620A2 (en) 1994-08-29 1996-03-07 Wake Forest University Lipid analogs for treating viral infections
US7135584B2 (en) 1995-08-07 2006-11-14 Wake Forest University Lipid analogs for treating viral infections
US5696277A (en) 1994-11-15 1997-12-09 Karl Y. Hostetler Antiviral prodrugs
AU706267B2 (en) 1994-11-30 1999-06-10 Supergen, Inc. Phosphocholine drug derivatives
US6177460B1 (en) * 1995-04-12 2001-01-23 The Procter & Gamble Company Method of treatment for cancer or viral infections
US5997898A (en) 1995-06-06 1999-12-07 Imarx Pharmaceutical Corp. Stabilized compositions of fluorinated amphiphiles for methods of therapeutic delivery
US5798374A (en) * 1995-06-07 1998-08-25 Sugen Inc. Methods of inhibiting phosphatase activity and treatment of disorders associated therewith
US6388076B1 (en) * 1995-06-19 2002-05-14 Ontogen Corporation Protein tyrosine phosphatase-inhibiting compounds
US6207145B1 (en) * 1997-05-09 2001-03-27 Pharma Pacific Pty Ltd. Therapeutic applications of high dose interferon
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
DK0914116T3 (da) 1996-05-22 2000-11-20 Protarga Inc Kompositstoffer omfattende konjugater af cis-docosahexaensyre og Taxotere
US6020179A (en) * 1996-10-03 2000-02-01 Incyte Pharmaceuticals, Inc. Nucleic acids encoding human tyrosine phosphatases
JP2001526639A (ja) * 1997-04-02 2001-12-18 アマーシャム・ファルマシア・バイオテック・ユーケイ・リミテッド 三環式塩基類似体
JPH1191623A (ja) 1997-09-18 1999-04-06 Unisia Jecs Corp キャブサスペンション制御装置
US6262044B1 (en) * 1998-03-12 2001-07-17 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (PTPASES)
IN183330B (sl) * 1998-03-23 1999-11-20 Dalmia Ct For Biotechnology
US6022029A (en) 1998-06-19 2000-02-08 Yukiwa Seiko Kabushiki Kaisha Chuck assembly
US6013646A (en) 1998-07-02 2000-01-11 Bayer Corporation Indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer
DE19845798A1 (de) 1998-09-29 2000-04-13 Schering Ag Verwendung von Neoangiogenese-Markern für Diagnose und Therapie von Tumoren, diese enthaltende Mittel, sowie Verfahren zu deren Herstellung
US6258582B1 (en) * 1998-09-30 2001-07-10 Millennium Pharmaceuticals, Inc. CSAPTP nucleic acid molecules and uses therefor
AU6074699A (en) 1998-10-13 2000-05-01 Mcgill University Pharmaceutical composition of glutathione modulators with antimony and/or arsenic for cancer therapy
US6890904B1 (en) 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
AU778588B2 (en) 1999-10-19 2004-12-09 Merck Sharp & Dohme Corp. Tyrosine kinase inhibitors
US6670341B1 (en) 1999-10-28 2003-12-30 Wake Forest University Health Sciences Compositions and methods for double-targeting virus infections and targeting cancer cells
US7026469B2 (en) 2000-10-19 2006-04-11 Wake Forest University School Of Medicine Compositions and methods of double-targeting virus infections and cancer cells
CA2388044A1 (en) 1999-11-09 2001-05-17 Alcon, Inc. Hydroxyeicosatetraenoate salts, compositions and methods of use in treating dry eye disorders
PT1231910E (pt) 1999-11-16 2009-08-06 Oncozyme Pharma Inc Pentamidina para tratar o cancro
JP4397503B2 (ja) 2000-03-30 2010-01-13 アスモ株式会社 回転電機のヨークの製造方法
WO2001074853A2 (en) 2000-04-03 2001-10-11 Massachusetts Institute Of Technology Methods and products for regulating cell motility
EP1301794B1 (en) 2000-04-14 2009-04-01 Ventana Medical Systems, Inc. Method for quantification of akt protein expression
JP5409981B2 (ja) 2000-05-15 2014-02-05 セルジーン コーポレイション 癌治療用の組成物および方法
CA2308994A1 (en) 2000-05-19 2001-11-19 Aegera Therapeutics Inc. Neuroprotective compounds
US7309696B2 (en) 2000-10-19 2007-12-18 Wake Forest University Compositions and methods for targeting cancer cells
US6569853B1 (en) * 2000-11-06 2003-05-27 Combinatorx, Incorporated Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders
EP1354196B1 (en) 2000-11-27 2010-09-15 Minerva Biotechnologies Corporation Diagnostics, drug screening and treatment for cancer
US20020128228A1 (en) 2000-12-01 2002-09-12 Wen-Jen Hwu Compositions and methods for the treatment of cancer
UA80393C2 (uk) 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці
EP1351678A2 (en) 2001-01-02 2003-10-15 Elizabeth Shanahan-Prendergast Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
US6693125B2 (en) * 2001-01-24 2004-02-17 Combinatorx Incorporated Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders
WO2002069949A2 (en) 2001-03-06 2002-09-12 Prendergast Patrick T Combination therapy for reduction of toxycity of chemotherapeutic agents
RU2299883C2 (ru) 2001-04-18 2007-05-27 Эро-Селтик, С.А. Соединения спиропиразола, содержащая их фармацевтическая композиция, способ модуляции опиоидного рецептора и способ лечения с применением таких соединений
CA2443938C (en) 2001-04-18 2010-06-22 R. Richard Goehring Spiroindene and spiroindane compounds as opioid ligands useful for treating pain
SI1385518T1 (sl) 2001-04-18 2009-02-28 Euro Celtique Sa Benzimidazolonske spojine
US20040072824A1 (en) 2001-06-01 2004-04-15 Adam Telerman Methods and compositions for the treatment of cancer
WO2002101353A2 (en) 2001-06-08 2002-12-19 U.S. Genomics, Inc. Methods and products for analyzing nucleic acids based on methylation status
WO2002100172A1 (en) 2001-06-11 2002-12-19 Xenoport, Inc. Administration of agents via the pept-2 transporter
US20030119741A1 (en) 2001-11-09 2003-06-26 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and aprotinin polypeptides
US20040116462A1 (en) 2002-12-12 2004-06-17 Mitsunori Ono Indolizine compounds
AU2002365258A1 (en) 2001-10-12 2003-09-02 University Of Vermont And State Agricultural College Binding peptides specific for the extracellular domain of erbb2 and uses therefor
US20030119747A1 (en) 2001-11-01 2003-06-26 Lanser Marc E. Methods of using pharmaceutical compositions comprising troponin subunits and homologs thereof before, during, or after surgical resection or radiologic ablation of a solid tumor
US20040038322A1 (en) 2002-01-22 2004-02-26 Regents Of The University Of California Potentiation of cancer therapies by ZNF217 inhibition
JP2005533001A (ja) 2002-03-04 2005-11-04 メディミューン，インコーポレーテッド インテグリンαｖβ３アンタゴニストを他の物質と併用投与する癌の予防または治療方法
US7351729B2 (en) 2002-03-08 2008-04-01 Signal Pharmaceuticals, Llc JNK inhibitors for use in combination therapy for treating or managing proliferative disorders and cancers
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US6620838B1 (en) 2002-04-19 2003-09-16 Signal Pharmaceuticals, Inc. Benzopyrazone compounds, compositions thereof, and methods of treatment therewith
AU2003303301B2 (en) 2002-05-03 2008-08-07 Massachusetts Institute Of Technology Delta4,5 glycuronidase and uses thereof
CA2485548A1 (en) 2002-05-10 2004-02-19 Purdue Research Foundation Epha2 agonistic monoclonal antibodies and methods of use thereof
JP4557714B2 (ja) 2002-05-10 2010-10-06 メディミューン，エルエルシー ＥｐｈＡ２モノクローナル抗体およびその使用法
WO2003097835A2 (en) 2002-05-16 2003-11-27 Molecular Engines Laboratories Pharmaceutical compositions for the treatment of cancer
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US20040034084A1 (en) 2002-05-24 2004-02-19 Celgene Corporation Methods for using JNK inhibitors for treating or preventing disease-related wasting
DE10228103A1 (de) 2002-06-24 2004-01-15 Bayer Cropscience Ag Fungizide Wirkstoffkombinationen
JP2006506442A (ja) 2002-07-09 2006-02-23 ポイント セラピューティクス， インコーポレイテッド ボロプロリン化合物併用療法
US20040072755A1 (en) 2002-07-12 2004-04-15 Stennicke Henning Ralf TF antagonist
US7521071B2 (en) 2002-10-09 2009-04-21 Versitech Limited Formulation of oral compositions comprising arsenic trioxide and methods of use thereof
KR20090048520A (ko) 2002-11-06 2009-05-13 셀진 코포레이션 암 및 다른 질환의 치료 및 관리를 위한 선택적 시토킨 억제 약물의 사용 방법 및 그 조성물
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US7230012B2 (en) 2002-11-14 2007-06-12 Celgene Corporation Pharmaceutical compositions and dosage forms of thalidomide
CA2506442A1 (en) 2002-11-18 2004-07-01 Celgene Corporation Methods of using and compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
US20040156828A1 (en) 2003-01-07 2004-08-12 Ruian Xu Adeno-associated virus mediated B7.1 vaccination synergizes with angiostatin to eradicate disseminated liver metastatic cancers
TWI330079B (en) 2003-01-15 2010-09-11 Synta Pharmaceuticals Corp Treatment for cancers
US20040146514A1 (en) 2003-01-21 2004-07-29 Smith James R. Cancer therapy using multiple antibodies from different species directed against the tumor3
WO2004065572A2 (en) 2003-01-23 2004-08-05 Molecular Engines Laboratories Proteic binding partners of tctp and methods of modulating tumor reversion or cell apoptosis
CA2524478A1 (en) 2003-05-02 2004-11-18 Aronex Pharmaceuticals, Inc. Lipid platinum complexes and methods of use thereof
EP1663153A4 (en) 2003-05-20 2011-01-05 Aronex Pharmaceuticals Inc COMBINATION SCHEMOTHERAPY WITH A LIPOSOMAL PLATINUM COMPLEX
DE10351068B4 (de) 2003-10-30 2006-06-22 Hauni Maschinenbau Ag Staffeltrommel
ES2629682T3 (es) 2004-03-29 2017-08-14 University Of South Florida Tratamiento efectivo de tumores y cáncer con fosfato de triciribina
US20100028339A1 (en) 2004-03-29 2010-02-04 Cheng Jin Q Compositions including triciribine and trastuzumab and methods of use thereof
EP1748772A2 (en) 2004-04-09 2007-02-07 University Of South Florida Combination therapies for cancer and proliferative angiopathies

Also Published As

Publication number Publication date
US20150320784A1 (en) 2015-11-12
EP2574341B1 (en) 2017-03-29
KR20070085094A (ko) 2007-08-27
JP2007530705A (ja) 2007-11-01
CA2561513A1 (en) 2005-10-13
US20140303110A1 (en) 2014-10-09
ES2629682T3 (es) 2017-08-14
EP1737472B1 (en) 2014-08-13
JP5647759B2 (ja) 2015-01-07
LT2574341T (lt) 2017-09-11
EP2574341A1 (en) 2013-04-03
HUE032657T2 (en) 2017-10-30
US8435959B2 (en) 2013-05-07
US9115162B2 (en) 2015-08-25
EP2574341A8 (en) 2013-05-22
KR101173969B1 (ko) 2012-08-16
PT2574341T (pt) 2017-07-03
CA2561513C (en) 2019-02-26
CN1984663A (zh) 2007-06-20
WO2005094322A2 (en) 2005-10-13
EP1737472A2 (en) 2007-01-03
DK2574341T3 (en) 2017-06-26
MXPA06011219A (es) 2007-05-08
EP1737472A4 (en) 2010-09-01
WO2005094322A3 (en) 2005-12-29
US20060247188A1 (en) 2006-11-02
US9518079B2 (en) 2016-12-13
CY1119224T1 (el) 2018-02-14
AU2005228410A1 (en) 2005-10-13
PL2574341T3 (pl) 2017-09-29

Similar Documents

Publication Publication Date Title
PL2574341T3 (pl) Efektywne leczenie guzów i raka fosforanem tricyrybiny
EP1811844A4 (en) METHOD FOR THE DIAGNOSIS AND TREATMENT OF CANCER
EP1968607A4 (en) TREATMENT OF CANCER AND OTHER DISEASES
HK1204476A1 (en) Compounds and methods for treatment of cancer
IL178012A0 (en) Diphenyl-indol-2-on compounds and their use in the treatment of cancer
EP1814909A4 (en) USE OF AIMP2DX2 FOR THE DIAGNOSIS AND TREATMENT OF CANCER
AU2003302892A8 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
EP1667680A4 (en) COMBINED METHODS OF TREATING CANCER
IL179738A0 (en) Mitochondrially targeted antioxidants in the treatment of liver diseases and epithelial cancers
IL185463A0 (en) Therapy of prostate cancer with ctla4 antibodies and hormonal therapy
EP1756166A4 (en) DIAGNOSIS AND TREATMENT OF PROSTATE CANCER
EP1587837A3 (en) Prostate cancer diagnosis and treatment
EP2012798A4 (en) USE OF INOSITOL-TRIPYROPHOSPHATE IN THE TREATMENT OF TUMORS AND DISEASES
EP1989216A4 (en) DIAGNOSIS AND TREATMENT OF PROSTATE CANCER
EP1934331A4 (en) PAX2 AS A TARGET FOR THE INDUCTION OF DEFB1-MEDIATED TUMORIMMUNITY AND CANCER THERAPY
IL202393A0 (en) Cancer treatment combination therapy comprising vinflunine and trastuzumab
WO2004104039A8 (en) Tumor antigens for prevention and/or treatment of cancer
HK1105288A1 (en) Flavopereirine and alstonine combinations in the treatment and prevention of prostate cancer
ZA200709542B (en) Combination therapy in the treatment of cancer
GB0326578D0 (en) Cancer diagnosis and therapy
EP1973398A4 (en) USE OF INOSITE TRIPYROPHOSPHATE IN THE TREATMENT OF TUMORS AND DISEASES
AU2003231803A8 (en) Treatment of cancer with mefloquire
EP1684795A4 (en) METHODS AND AGENTS FOR THE TREATMENT OF CANCER
EP1646385A4 (en) USE OF BENZOTHIOPHENES TO TREAT AND PREVENT PROSTATE CANCER
EP1766051A4 (en) METHOD FOR IDENTIFYING BREAST CANCER RISK AND TREATMENTS THEREOF